Division of General Internal Medicine, Medical College of Wisconsin, General Internal Medicine-CLCC, Milwaukee, Wisconsin 53226, USA.
Am J Epidemiol. 2010 Sep 15;172(6):637-44. doi: 10.1093/aje/kwq220. Epub 2010 Jul 21.
Subject recruitment for epidemiologic studies is associated with major challenges due to privacy laws now common in many countries. Privacy policies regarding recruitment methods vary tremendously across institutions, partly because of a paucity of information about what methods are acceptable to potential subjects. The authors report the utility of an opt-out method without prior physician notification for recruiting community-dwelling US women aged 65 years or older with incident breast cancer in 2003. Participants (n = 3,083) and possibly eligible nonparticipants (n = 2,664) were compared using characteristics derived from billing claims. Participation for persons with traceable contact information was 70% initially (2005-2006) and remained over 90% for 3 follow-up surveys (2006-2008). Older subjects and those living in New York State were less likely to participate, but participation did not differ on the basis of socioeconomic status, race/ethnicity, underlying health, or type of cancer treatment. Few privacy concerns were raised by potential subjects, and no complaints were lodged. Using opt-out methods without prior physician notification, a population-based cohort of older breast cancer subjects was successfully recruited. This strategy may be applicable to population-based studies of other diseases and is relevant to privacy boards making decisions about recruitment strategies acceptable to the public.
由于现在许多国家都普遍存在隐私法,因此,流行病学研究的受试者招募工作面临着重大挑战。各机构的招聘方法隐私政策差异很大,部分原因是缺乏有关哪些方法可以被潜在受试者接受的信息。作者报告了一种无需事先通知医生即可选择退出的方法的效用,该方法用于在 2003 年招募居住在社区的美国 65 岁及以上、患有新发乳腺癌的女性。使用从计费索赔中得出的特征,对参与者(n=3083)和可能符合条件的非参与者(n=2664)进行了比较。对于可追踪联系信息的人,最初的参与率为 70%(2005-2006 年),在 3 次后续调查(2006-2008 年)中,参与率仍保持在 90%以上。年龄较大的受试者和居住在纽约州的受试者不太可能参与,但参与率与社会经济地位、种族/族裔、基础健康或癌症治疗类型无关。潜在受试者提出的隐私问题很少,也没有提出投诉。在没有事先通知医生的情况下使用选择退出方法,成功招募了一组基于人群的老年乳腺癌患者队列。这种策略可能适用于其他疾病的基于人群的研究,并且与隐私委员会就公众可接受的招募策略做出决策有关。